In contrast to GBM, epithelial ovarian cancer, CRC, and NSCLC, showed to have a higher PDE10A expression that contributes to tumor progression, therapy resistance, and reduced patient survival (6, 12, 211). This evidence concerns the gene PDE10A and ovarian carcinoma.